Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | withdrawn | Phase 1 | 0 | University of MinnesotaOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04332549 |
| To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer |
| withdrawn |
| Phase 1 |
| 0 |
| Sun Pharma Advanced Research Company LimitedINDUSTRY |
| 1 |
| Jun 1, 2020 |
| clinicaltrials |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 | clinicaltrials |
| NCT04044378 | Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma | withdrawn | Phase 1 / Phase 2 | 0 | Peking University People's HospitalOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")(GLACIER) | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care(Toca7) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT02619669 | Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | withdrawn | Phase 1 | 0 | Gary SchwartzOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT03721211 | Imaging With [11C]Martinostat in Breast Cancer | withdrawn | Phase 1 | 0 | Christine Elizabeth EdmondsOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin(iTRAP) | withdrawn | Phase 1 | 0 | Queen Mary University of LondonOTHER | 0 | Feb 25, 2020 | clinicaltrials |
| NCT04158700 | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 19, 2020 | clinicaltrials |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | Darell BignerOTHER | 0 | Feb 11, 2020 | clinicaltrials |
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma(PPD1) | withdrawn | Phase 1 | 0 | Darell BignerOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03110445 | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus(rVV-740CTA) | withdrawn | Phase 1 | 0 | University Hospital, Basel, SwitzerlandOTHER | 0 | Feb 7, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | withdrawn | Phase 1 | 0 | CTI BioPharmaINDUSTRY | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02018419 | Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients(MBC) | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02274506 | Infusion of Allogeneic, 3rd Party CD19-specific T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03611985 | Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03760445 | HDM201 Added to CT in R/R or Newly Diagnosed AML | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jan 9, 2020 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00880854 | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | withdrawn | Phase 1 | 0 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | withdrawn | Phase 1 | 0 | Celyad Oncology SAINDUSTRY | 0 | Oct 29, 2019 | clinicaltrials |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT02709993 | Consolidation Therapy in Patients With Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Kiromic BioPharma Inc.INDUSTRY | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 10, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2020source: clinicaltrials